| UDR |
Report |
FFO as Adjusted per diluted share |
BEAT |
pred ~$0.64 vs. cons $0.63 |
MEDIUM |
| UDR |
Report |
Same-store revenue growth |
BEAT |
pred ~1.5% vs. cons 1.3% |
MEDIUM |
| UDR |
Report |
Same-store NOI growth |
BEAT |
pred ~0.5% vs. cons 0.2% |
LOW |
| UDR |
Guide |
FY2026 FFO as Adjusted per diluted share guidance |
UNCHANGED |
guide ~$2.52 vs. cons $2.52 (FY2026) |
HIGH |
| UDR |
Guide |
FY2026 same-store NOI growth guidance |
UNCHANGED |
guide ~0.13% vs. cons 0.13% (FY2026) |
MEDIUM |
| UDR |
Guide |
3Q2026 FFO as Adjusted per diluted share outlook |
LOWER |
guide ~$0.63 vs. cons $0.64 (3Q2026) |
LOW |
| UDR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| UDR |
Return |
5-day cumulative residual |
+1.5% (STABILIZE) |
A modest FFOA and same-store operating beat should support the initial move, but unchanged FY2026 FFOA and NOI guidance leaves limited out-period estimate revision; the initial gain should stabilize rather than extend materially. |
MEDIUM |